Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brixelle
- Development stage
- Unknown
- Lead developer
- Bilix
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Brixelle (BX-001N) is a synthetic, self-assembling mono-PEGylated bilirubin-3α nanoparticle developed by Bilix. It is designed to overcome the water-insolubility, instability, and toxicity of free bilirubin while retaining its potent antioxidant and anti-inflammatory properties. Brixelle consists of a synthetic bilirubin core covalently conjugated to polyethylene glycol (PEG) chains, allowing it to self-assemble into uniform nanoparticles in aqueous media. It acts as a reactive oxygen species (ROS) scavenger and immunomodulator, preferentially accumulating in injured tissues (such as ischemic kidneys) via the enhanced permeability and retention (EPR) effect. Brixelle is primarily being developed for the prevention and treatment of ischemia-reperfusion injury (IRI), including cardiac surgery-associated acute kidney injury (CSA-AKI) and transplantation-related IRI.
- Brand names
- Brixelle
- Other names
- PEGylated bilirubin nanoparticlesbilirubin nanoparticlespolyethylene glycol-conjugated bilirubin nanoparticlessynthetic mono-PEGylated bilirubin-3α nanoparticle
Beyond the preview
Go deeper on Brixelle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Brixelle.